Clinical Trial Update: Study of TYK-00540 Combined With Enzalutamide in Patients With Metastatic Castration-resistant Prostate Cancer（mCRPC） [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluating TYK-00540 in combination with enzalutamide for metastatic castration-resistant prostate cancer (mCRPC). The study status i…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer

Drugs mentioned

• Enzalutamide (enzalutamide)
• TYK-00540 (TYK-00540)

Snippet

Sponsor: TYK Medicines, Inc | Conditions: mCRPC | Phase 1, Phase 2 | Status: NOT_YET_RECRUITING